TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00810732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open
Description: Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for sitaxsentan, orally administered once daily (double blind arm)
Study: NCT00724464

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)
Description: Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.

Intervention type: DRUG
Intervention: Rebetol (ribavirin)
Description: Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
Study: NCT03119727

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeO2
Description: All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
Study: NCT01847170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Study: NCT00524199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: 12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
Study: NCT03350100

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance
Description: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance
Description: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance
Description: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
Study: NCT04961866

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: parenteral protein 1 g/kg
Description: patients received 1 g/ kg of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition 2 g/kg
Description: Patients received 2 g/ kg of protein
Study: NCT02136433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet - self exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GRASP self exercise
Study: NCT02595216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound System
Description: The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
Study: NCT00601484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119
Description: PF-04383119 200 mcg/kg IV, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo IV, single dose
Study: NCT04744740

Intervention type: DEVICE
Intervention: in-home sleep recording
Description: in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
Study: NCT03324880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH (1-84)
Description: rhPTH (1-84) SC injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD SC injection.
Study: NCT01036022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1399686
Description: Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1399686
Description: Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1399686
Description: Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
Study: NCT01257711

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y or Billroth II
Description: Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y or Billroth II
Description: Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
Study: NCT03991832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
Study: NCT02783729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem tartrate
Description: Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem-matched placebo
Description: Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem-matched placebo
Description: Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study: NCT03300570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolcanatide
Description: Given PO
Study: NCT02783729

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem-matched placebo
Description: Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study: NCT03300570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02807428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 660 mg/6 mL
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 6 mL
Description: 6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study: NCT00829335

Intervention type: PROCEDURE
Intervention: IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION
Description: Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
Study: NCT04588935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol; Perindopril;
Description: based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
Study: NCT03217435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal epithelial allograft
Description: A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal conjunctival allograft
Description: A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
Study: NCT03991832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
Study: NCT03217435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diamond knife
Description: A diamond knife to create a particular shaped limbal graft for transplantation
Study: NCT04305002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Injections, 2 mg once weekly for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections, once weekly for 18 months
Study: NCT04189263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted dietary intervention
Description: Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care aromatase inhibitors
Description: standard of care aromatase inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care aromatase inhibitors
Description: standard of care aromatase inhibitors
Study: NCT02810093

Intervention type: OTHER
Intervention: retrospective medical records analyze
Description: Ten thousand medical records (between years 2000 and 2016) will be analyzed
Study: NCT01481545

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofolinic acid
Description: 250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
Study: NCT02503683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-AAT
Description: Single or multiple doses of ALN-AAT by subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: calculated volume to match active comparator
Study: NCT04534634

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IFN-α combined with CAR-T cell therapy
Description: Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m\^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10\^7/kg, intravenously infusion.
Study: NCT04021186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention of hyperglycemia
Description: Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
Study: NCT01919970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This condition involves 12 weekly CBT sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
Study: NCT02815995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Study: NCT00990340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-jet® containing TevTropin®
Description: Needle-free delivery method for 14 days before cross-over to other arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TevTropin® needle-syringe injection method
Description: comparison of delivery methods for 14 days before cross-over to other arm
Study: NCT04108195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Participants will receive talquetamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Participants will receive talquetamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Participants will receive teclistamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Participants will receive teclistamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Participants will receive pomalidomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Participants will receive pomalidomide.
Study: NCT03803891

Intervention type: PROCEDURE
Intervention: Endoscopic full-thickness resection
Description: Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
Study: NCT03718962

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surrounding needling+ phototherapy
Description: Surrounding needling+ phototherapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy
Description: phototherapy
Study: NCT04015700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics
Description: -The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA®2000 EP Device supplied by Geneos Therapeutics
Description: CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmid encoded IL-12
Description: The INO-9012 vials will be supplied by Geneos Therapeutics
Study: NCT01876927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOX 4 cycles - Surgery
Description: DOX 4 cycles - Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOX 2 cycles - Surgery - DOX 2 cycles
Description: DOX 2 cycles - Surgery - DOX 2 cycles
Study: NCT01696734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04070469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: dosage of plasma concentration of amoxicillin